Cell Therapy News Volume 24.29 | Aug 28 2023

    By
    Jamie Kang
    -
    0
    17







    2023-08-28 | CTN 24.29


    Cell Therapy News by STEMCELL Technologies
    Vol. 24.29 – 28 August, 2023
    TOP STORY

    RBFOX2 Recognizes N6-Methyladenosine to Suppress Transcription and Block Myeloid Leukaemia Differentiation

    Scientists presented a pathway of m6A methyltransferase complex recruitment and m6A deposition on chromatin-associated RNAs, resulting in locus-selective chromatin regulation, which has potential therapeutic implications in leukemia.
    [Nature Cell Biology]

    Full Article
    Learn how to be a great STEM mentor to new lab members
    PUBLICATIONSRanked by the impact factor of the journal

    Laponite Lights Calcium Flickers by Reprogramming Lysosomes to Steer DC Migration for an Effective Antiviral CD8+ T Cell Response

    The effect of laponite (Lap) on dendritic cells (DCs), which could be internalized into lysosomes and induced cytoskeletal reorganization via the lysosomal reprogramming–calcium flicker axis, was evaluated, and it was found that Lap dramatically improved the in vivo homing ability of these DCs to lymphoid tissues.
    [Advanced Science]

    Full Article

    Combination Human Umbilical Cord Perivascular and Endothelial Colony Forming Cell Therapy for Ischemic Cardiac Injury

    Endothelial colony-forming cells (ECFCs) were expanded from rat bone marrow isolates. Based on the time of culture, morphology, and immunophenotype, ECFCs with “late” endothelial progenitor cell characteristics were co-injected with first-trimester human umbilical cord perivascular cells in the ischemic rat myocardium.
    [NPJ Regenerative Medicine]

    Full Article

    CRTAC1 Enhances the Chemosensitivity of Non-small Cell Lung Cancer to Cisplatin by Eliciting RyR-Mediated Calcium Release and Inhibiting Akt1 Expression

    Results obtained from analyses of the Gene Expression Omnibus database of non-small cell lung cancer patients showed that cartilage acidic protein 1 (CRTAC1) played a role in the response to platinum-based chemotherapy.
    [Cell Death & Disease]

    Full Article

    Attenuated Salmonella Carrying siRNA-PD-L1 and Radiation Combinatorial Therapy Induces Tumor Regression on HCC Through T Cell-Mediated Immuno-Enhancement

    Investigators utilized attenuated Salmonella as a carrier to explore whether attenuated Salmonella carrying siRNA-PD-L1 could effectively enhance the antitumor effect of radiotherapy on hepatocellular carcinoma (HCC)-bearing mice.
    [Cell Death Discovery]

    Full ArticleGraphical Abstract

    Dual Targeting Ovarian Cancer by Muc16 CAR T Cells Secreting a Bispecific T Cell Engager Antibody for an Intracellular Tumor Antigen WT1

    Researchers described an engineered cell with both dual targeting and orthogonal cytotoxic modalities directed against two tumor antigens that are highly expressed on ovarian cancer cells: cell surface Muc16 and intracellular WT1.
    [Cancer Immunology Immunotherapy]

    Abstract

    Adoptive Immunotherapy via Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real World, Retrospective Multi-Centre Study

    Investigators performed a retrospective ‘real world’ analysis of a multicentre cohort of myelofibrosis allogeneic hematopoietic cell transplantation patients from 8 European transplant centers who received donor lymphocyte infusions between 2005-2022.
    [Transplantation And Cellular Therapy]

    Full Article

    Autologous Stem Cell Transplantation in Adult Patients with Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission and No Detectable Minimal Residual Disease. A Comparative Retrospective Study with Haploidentical Transplants of the Global Committee and the ALWP of the EBMT

    Researchers compared the outcome of post autologous stem cell transplantation or haploidentical transplants in patients with intermediate-risk acute myeloid leukemia achieving first complete remission and measurable residual disease negativity at pretransplant in the period from 2010 to 2021.
    [Bone Marrow Transplantation]

    Full Article

    Clinical Outcomes in Transplant-Eligible Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma after Second-Line Salvage Chemotherapy: A Retrospective Study

    Scientists demonstrated that chemosensitivity remained a crucial factor in predicting survival outcomes following CAR T-cell therapy irrespective of the administration timing and that both autologous hematopoietic stem cell transplantation and CAR T-cell therapy were acceptable.
    [Cancer Medicine]

    Full Article
    Explore the Science Events Calendar to discover conferences, podcasts, webinars, and more!
    REVIEWS

    Who Wins the Combat, CAR or TCR?

    The authors discuss the parallel comparisons between CARs and T cell receptors (TCRs) from various aspects and how these current findings might provide novel insights and contribute to the improvement of CAR-T cell therapy efficacy.
    [Leukemia]

    Abstract
    INDUSTRY AND POLICY NEWS

    Taysha Gene Therapies Announces Fast Track Designation Granted by US FDA for TSHA-102 in Rett Syndrome

    Taysha Gene Therapies, Inc. announced the US FDA has granted Fast Track Designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
    [Taysha Gene Therapies, Inc.]

    Press Release

    Precision, Pivoting to In Vivo Editing, Punts Early-Phase CAR-T to Imugene for $21M Upfront

    Precision BioSciences has moved quickly to partner its CAR-T cell therapy candidate. Less than three weeks after confirming it planned to partner the program, the biotech has agreed to offload the asset to Imugene for $21 million upfront and much more on the back end.
    [Fierce Biotech]

    Editorial
    FEATURED EVENT

    Cell Therapy Analytics Symposium

    September 19, 2023
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Staff Scientist – GMP for Stem Cell Therapies

    City of Hope – Duarte, California United States

    Associate Professor – Cancer Immunology and Immunotherapy

    Baylor College of Medicine – Houston, Texas, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Research Associate – T Cell Immunotherapy

    City of Hope – Duarte, California, United States

    Assistant Professor – Immunology

    Harvard Medical School – Boston, Massachusetts, United States
    Brought to you by

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter